{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:22:47Z","timestamp":1790713367441,"version":"4.1.0"},"reference-count":169,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T00:00:00Z","timestamp":1543449600000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030_152639\/1"],"award-info":[{"award-number":["310030_152639\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["FP7-INNOVATION I HEALTH-F2-2013-602114"],"award-info":[{"award-number":["FP7-INNOVATION I HEALTH-F2-2013-602114"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.vph.2017.10.003","type":"journal-article","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T22:01:24Z","timestamp":1508191284000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["Update on the role of Pentraxin 3 in atherosclerosis and cardiovascular diseases"],"prefix":"10.1016","volume":"99","author":[{"given":"Matteo","family":"Casula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0823-8729","authenticated-orcid":false,"given":"Fabrizio","family":"Montecucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4747-5535","authenticated-orcid":false,"given":"Aldo","family":"Bonaventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1472-7975","authenticated-orcid":false,"given":"Luca","family":"Liberale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vecchi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Dallegri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.vph.2017.10.003_bb0005","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","article-title":"Inflammation in atherosclerosis","volume":"32","author":"Libby","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"27","key":"10.1016\/j.vph.2017.10.003_bb0010","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/eurheartj\/ehu203","article-title":"Anti-inflammatory therapies for cardiovascular disease","volume":"35","author":"Ridker","year":"2014","journal-title":"Eur. Heart J."},{"issue":"37","key":"10.1016\/j.vph.2017.10.003_bb0015","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.2174\/1381612822666160822124546","article-title":"Targeting inflammation in primary cardiovascular prevention","volume":"22","author":"Carbone","year":"2016","journal-title":"Curr. Pharm. Des."},{"issue":"3","key":"10.1016\/j.vph.2017.10.003_bb0020","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","article-title":"Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.vph.2017.10.003_bb0025","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction","volume":"367","author":"Emerging Risk Factors","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.vph.2017.10.003_bb0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/ije\/dyn217","article-title":"Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts","volume":"38","author":"Shah","year":"2009","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.vph.2017.10.003_bb0035","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.vph.2015.05.001","article-title":"Biological actions of pentraxins","volume":"73","author":"Vilahur","year":"2015","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.vph.2017.10.003_bb0040","doi-asserted-by":"crossref","first-page":"725102","DOI":"10.1155\/2013\/725102","article-title":"Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases","volume":"2013","author":"Bonacina","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.vph.2017.10.003_bb0045","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1146\/annurev.immunol.23.021704.115756","article-title":"Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility","volume":"23","author":"Garlanda","year":"2005","journal-title":"Annu. Rev. Immunol."},{"issue":"52","key":"10.1016\/j.vph.2017.10.003_bb0050","doi-asserted-by":"crossref","first-page":"32817","DOI":"10.1074\/jbc.272.52.32817","article-title":"Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component","volume":"272","author":"Bottazzi","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.vph.2017.10.003_bb0055","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1582-4934.2007.00061.x","article-title":"Role of the soluble pattern recognition receptor PTX3 in vascular biology","volume":"11","author":"Presta","year":"2007","journal-title":"J. Cell. Mol. Med."},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0060","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08916934.2011.611549","article-title":"Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications","volume":"45","author":"Cieslik","year":"2012","journal-title":"Autoimmunity"},{"issue":"43","key":"10.1016\/j.vph.2017.10.003_bb0065","doi-asserted-by":"crossref","first-page":"25584","DOI":"10.1074\/jbc.270.43.25584","article-title":"Promoter structure and transcriptional activation of the murine TSG-14 gene encoding a tumor necrosis factor\/interleukin-1-inducible pentraxin protein","volume":"270","author":"Altmeyer","year":"1995","journal-title":"J. Biol. Chem."},{"issue":"13","key":"10.1016\/j.vph.2017.10.003_bb0070","doi-asserted-by":"crossref","first-page":"8172","DOI":"10.1074\/jbc.272.13.8172","article-title":"Characterization of the promoter for the human long pentraxin PTX3. Role of NF-kappaB in tumor necrosis factor-alpha and interleukin-1beta regulation","volume":"272","author":"Basile","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0075","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/immu.200310022","article-title":"Biochemical and functional characterization of the interaction between pentraxin 3 and C1q","volume":"33","author":"Nauta","year":"2003","journal-title":"Eur. J. Immunol."},{"issue":"12","key":"10.1016\/j.vph.2017.10.003_bb0080","doi-asserted-by":"crossref","first-page":"8433","DOI":"10.4049\/jimmunol.181.12.8433","article-title":"Binding of the long pentraxin PTX3 to factor H: interacting domains and function in the regulation of complement activation","volume":"181","author":"Deban","year":"2008","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.vph.2017.10.003_bb0085","doi-asserted-by":"crossref","first-page":"e23991","DOI":"10.1371\/journal.pone.0023991","article-title":"Human pentraxin 3 binds to the complement regulator c4b-binding protein","volume":"6","author":"Braunschweig","year":"2011","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.vph.2017.10.003_bb0090","doi-asserted-by":"crossref","first-page":"5815","DOI":"10.4049\/jimmunol.1100180","article-title":"M-ficolin interacts with the long pentraxin PTX3: a novel case of cross-talk between soluble pattern-recognition molecules","volume":"186","author":"Gout","year":"2011","journal-title":"J. Immunol."},{"issue":"41","key":"10.1016\/j.vph.2017.10.003_bb0095","doi-asserted-by":"crossref","first-page":"28263","DOI":"10.1074\/jbc.M109.009225","article-title":"Synergy between ficolin-2 and pentraxin 3 boosts innate immune recognition and complement deposition","volume":"284","author":"Ma","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.vph.2017.10.003_bb0100","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1074\/jbc.M110.190637","article-title":"Heterocomplexes of mannose-binding lectin and the pentraxins PTX3 or serum amyloid P component trigger cross-activation of the complement system","volume":"286","author":"Ma","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"24","key":"10.1016\/j.vph.2017.10.003_bb0105","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1182\/blood-2009-12-258376","article-title":"Role of complement and Fc{gamma} receptors in the protective activity of the long pentraxin PTX3 against Aspergillus fumigatus","volume":"116","author":"Moalli","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.vph.2017.10.003_bb0110","first-page":"48","article-title":"Quantitative electroencephalographic parameters of patients with essential hypertension","volume":"18","author":"Berus","year":"1992","journal-title":"Fiziol. Cheloveka"},{"issue":"41","key":"10.1016\/j.vph.2017.10.003_bb0115","doi-asserted-by":"crossref","first-page":"30161","DOI":"10.1074\/jbc.M703738200","article-title":"PTX3 interacts with inter-alpha-trypsin inhibitor: implications for hyaluronan organization and cumulus oophorus expansion","volume":"282","author":"Scarchilli","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.vph.2017.10.003_bb0120","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood-2003-10-3433","article-title":"Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis","volume":"104","author":"Rusnati","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.vph.2017.10.003_bb0125","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ni0410-282","article-title":"Rolling back neutrophil adhesion","volume":"11","author":"McEver","year":"2010","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.vph.2017.10.003_bb0130","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.4049\/jimmunol.1002035","article-title":"The therapeutic potential of the humoral pattern recognition molecule PTX3 in chronic lung infection caused by Pseudomonas aeruginosa","volume":"186","author":"Moalli","year":"2011","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.vph.2017.10.003_bb0135","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.micinf.2005.12.017","article-title":"Dual function of the long pentraxin PTX3 in resistance against pulmonary infection with Klebsiella pneumoniae in transgenic mice","volume":"8","author":"Soares","year":"2006","journal-title":"Microbes Infect."},{"issue":"4","key":"10.1016\/j.vph.2017.10.003_bb0140","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1189\/jlb.0803371","article-title":"PTX3 function as an opsonin for the dectin-1-dependent internalization of zymosan by macrophages","volume":"75","author":"Diniz","year":"2004","journal-title":"J. Leukoc. Biol."},{"issue":"5","key":"10.1016\/j.vph.2017.10.003_bb0145","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.4049\/jimmunol.180.5.3391","article-title":"Antiviral activity of the long chain pentraxin PTX3 against influenza viruses","volume":"180","author":"Reading","year":"2008","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.vph.2017.10.003_bb0150","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/blood-2006-03-009266","article-title":"Pentraxin 3 protects from MCMV infection and reactivation through TLR sensing pathways leading to IRF3 activation","volume":"108","author":"Bozza","year":"2006","journal-title":"Blood"},{"issue":"6912","key":"10.1016\/j.vph.2017.10.003_bb0155","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature01195","article-title":"Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response","volume":"420","author":"Garlanda","year":"2002","journal-title":"Nature"},{"issue":"7224","key":"10.1016\/j.vph.2017.10.003_bb0160","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nature07468","article-title":"Structural recognition and functional activation of FcgammaR by innate pentraxins","volume":"456","author":"Lu","year":"2008","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.vph.2017.10.003_bb0165","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.coi.2008.05.004","article-title":"Pentraxins, humoral innate immunity and tissue injury","volume":"20","author":"Manfredi","year":"2008","journal-title":"Curr. Opin. Immunol."},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0170","doi-asserted-by":"crossref","first-page":"970","DOI":"10.4049\/jimmunol.1100261","article-title":"Early and transient release of leukocyte pentraxin 3 during acute myocardial infarction","volume":"187","author":"Maugeri","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.vph.2017.10.003_bb0175","first-page":"407","article-title":"P.C. Reading, E. Barbati, B. Bottazzi, C. Garlanda, A. Mantovani, The \"sweet\" side of a long pentraxin: how glycosylation affects PTX3 functions in innate immunity and inflammation","volume":"3","author":"Inforzato","year":"2012","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0180","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1161\/CIRCRESAHA.107.160697","article-title":"Protective role of CXC receptor 4\/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis","volume":"102","author":"Zernecke","year":"2008","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.vph.2017.10.003_bb0185","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1084\/jem.20061301","article-title":"The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps","volume":"204","author":"Jaillon","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.vph.2017.10.003_bb0190","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3389\/fimmu.2016.00344","article-title":"The Protective Effect against Extracellular Histones Afforded by Long-Pentraxin PTX3 as a Regulator of NETs","volume":"7","author":"Daigo","year":"2016","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.vph.2017.10.003_bb0195","doi-asserted-by":"crossref","first-page":"M111","DOI":"10.1074\/mcp.M111.015073","article-title":"The proteomic profile of circulating pentraxin 3 (PTX3) complex in sepsis demonstrates the interaction with azurocidin 1 and other components of neutrophil extracellular traps","volume":"11","author":"Daigo","year":"2012","journal-title":"Mol. Cell. Proteomics"},{"issue":"6","key":"10.1016\/j.vph.2017.10.003_bb0200","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1189\/jlb.69.6.928","article-title":"TSG-14 transgenic mice have improved survival to endotoxemia and to CLP-induced sepsis","volume":"69","author":"Dias","year":"2001","journal-title":"J. Leukoc. Biol."},{"issue":"4","key":"10.1016\/j.vph.2017.10.003_bb0205","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ni.1854","article-title":"Regulation of leukocyte recruitment by the long pentraxin PTX3","volume":"11","author":"Deban","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.vph.2017.10.003_bb0210","doi-asserted-by":"crossref","first-page":"920517","DOI":"10.1155\/2012\/920517","article-title":"Pentraxin 3(PTX 3): an endogenous modulator of the inflammatory response","volume":"2012","author":"Kunes","year":"2012","journal-title":"Mediat. Inflamm."},{"issue":"8","key":"10.1016\/j.vph.2017.10.003_bb0215","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jcmg.2012.01.020","article-title":"Coronary vasomotor control in obesity and morbid obesity: contrasting flow responses with endocannabinoids, leptin, and inflammation","volume":"5","author":"Quercioli","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"issue":"Suppl K","key":"10.1016\/j.vph.2017.10.003_bb0220","first-page":"78","article-title":"IL-1 inducible genes in human umbilical vein endothelial cells","volume":"14","author":"Introna","year":"1993","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.vph.2017.10.003_bb0225","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/ATVBAHA.107.158642","article-title":"Upregulation of pentraxin-3 in human endothelial cells after lysophosphatidic acid exposure","volume":"28","author":"Gustin","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.vph.2017.10.003_bb0230","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/bja\/aep298","article-title":"Regulation of pentraxin-3 by antioxidants","volume":"103","author":"Hill","year":"2009","journal-title":"Br. J. Anaesth."},{"issue":"11","key":"10.1016\/j.vph.2017.10.003_bb0235","first-page":"7699","article-title":"A key mediator, PTX3, of IKK\/IkappaB\/NF-kappaB exacerbates human umbilical vein endothelial cell injury and dysfunction","volume":"7","author":"Zhao","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"17","key":"10.1016\/j.vph.2017.10.003_bb0240","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1161\/CIRCULATIONAHA.114.014822","article-title":"Pentraxin 3 induces vascular endothelial dysfunction through a P-selectin\/matrix metalloproteinase-1 pathway","volume":"131","author":"Carrizzo","year":"2015","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.vph.2017.10.003_bb0245","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1161\/ATVBAHA.111.243998","article-title":"Long pentraxin 3\/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis","volume":"32","author":"Leali","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.vph.2017.10.003_bb0250","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/cvr\/cvw209","article-title":"Endothelial cell-derived pentraxin 3 limits the vasoreparative therapeutic potential of circulating angiogenic cells","volume":"112","author":"O'Neill","year":"2016","journal-title":"Cardiovasc. Res."},{"issue":"9","key":"10.1016\/j.vph.2017.10.003_bb0255","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.ATV.0000177807.54959.7d","article-title":"Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo","volume":"25","author":"Camozzi","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.vph.2017.10.003_bb0260","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.atherosclerosis.2007.05.031","article-title":"Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening","volume":"197","author":"Kotooka","year":"2008","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.vph.2017.10.003_bb0265","doi-asserted-by":"crossref","first-page":"372","DOI":"10.5551\/jat.26740","article-title":"Deficiency of long pentraxin PTX3 promoted neointimal hyperplasia after vascular injury","volume":"22","author":"Ishino","year":"2015","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.vph.2017.10.003_bb0270","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1038\/emm.2015.37","article-title":"Honokiol ameliorates endothelial dysfunction through suppression of PTX3 expression, a key mediator of IKK\/IkappaB\/NF-kappaB, in atherosclerotic cell model","volume":"47","author":"Qiu","year":"2015","journal-title":"Exp. Mol. Med."},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0275","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.atherosclerosis.2011.12.039","article-title":"The glucagon-like peptide 1 analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells","volume":"221","author":"Shiraki","year":"2012","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.vph.2017.10.003_bb0280","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2215\/CJN.04330808","article-title":"Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria","volume":"4","author":"Yilmaz","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"7","key":"10.1016\/j.vph.2017.10.003_bb0285","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.2215\/CJN.01110210","article-title":"Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation","volume":"5","author":"Yilmaz","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.vph.2017.10.003_bb0290","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2215\/CJN.09231010","article-title":"PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes","volume":"6","author":"Yilmaz","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.vph.2017.10.003_bb0295","doi-asserted-by":"crossref","first-page":"e63493","DOI":"10.1371\/journal.pone.0063493","article-title":"Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction","volume":"8","author":"Witasp","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0300","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40620-014-0045-4","article-title":"Pentraxin 3 as a novel bio-marker of inflammation and endothelial dysfunction in autosomal dominant polycystic kidney disease","volume":"27","author":"Kocyigit","year":"2014","journal-title":"J Nephrol"},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0305","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1536\/ihj.13-253","article-title":"Plasma pentraxin 3 is a more potent predictor of endothelial dysfunction than high-sensitive C-reactive protein","volume":"55","author":"Yasunaga","year":"2014","journal-title":"Int. Heart J."},{"issue":"7","key":"10.1016\/j.vph.2017.10.003_bb0310","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2215\/CJN.08660813","article-title":"The relationship between IL-10 levels and cardiovascular events in patients with CKD","volume":"9","author":"Yilmaz","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.vph.2017.10.003_bb0315","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4103\/1817-1737.160840","article-title":"Correlation between pentraxin-3 and endothelial dysfunction in obstructive sleep apnea syndrome","volume":"10","author":"Kanbay","year":"2015","journal-title":"Ann Thorac Med"},{"issue":"12","key":"10.1016\/j.vph.2017.10.003_bb0320","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.placenta.2012.09.009","article-title":"PTX3 as a potential endothelial dysfunction biomarker for severity of preeclampsia and IUGR","volume":"33","author":"Cozzi","year":"2012","journal-title":"Placenta"},{"key":"10.1016\/j.vph.2017.10.003_bb0325","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ejogrb.2014.09.027","article-title":"Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: a meta-analysis","volume":"182","author":"Allen","year":"2014","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0330","doi-asserted-by":"crossref","first-page":"220","DOI":"10.12891\/ceog1825.2015","article-title":"Plasma pentraxin 3 levels in preeclamptic patients","volume":"42","author":"Turkmen","year":"2015","journal-title":"Clin. Exp. Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.vph.2017.10.003_bb0335","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.preghy.2015.09.003","article-title":"Elevated inflammatory markers in preeclamptic pregnancies, but no relation to systemic arterial stiffness","volume":"5","author":"Estensen","year":"2015","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.vph.2017.10.003_bb0340","article-title":"Second-trimester maternal serum markers in the prediction of preeclampsia","author":"Luo","year":"2016","journal-title":"J. Perinat. Med."},{"issue":"9","key":"10.1016\/j.vph.2017.10.003_bb0345","doi-asserted-by":"crossref","first-page":"e45834","DOI":"10.1371\/journal.pone.0045834","article-title":"Human pentraxin 3 (PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension","volume":"7","author":"Tamura","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.vph.2017.10.003_bb0350","doi-asserted-by":"crossref","first-page":"e113086","DOI":"10.1371\/journal.pone.0113086","article-title":"Pentraxin3 in chronic thromboembolic pulmonary hypertension: a new biomarker for screening from remitted pulmonary thromboembolism","volume":"9","author":"Naito","year":"2014","journal-title":"PLoS One"},{"issue":"3 Suppl. 97","key":"10.1016\/j.vph.2017.10.003_bb0355","first-page":"S73","article-title":"Plasma pentraxin-3 levels in patients with Takayasu's arteritis during routine follow-up","volume":"34","author":"Alibaz-Oner","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.vph.2017.10.003_bb0360","doi-asserted-by":"crossref","first-page":"e0147091","DOI":"10.1371\/journal.pone.0147091","article-title":"Detection of anti-pentraxin-3 autoantibodies in ANCA-associated vasculitis","volume":"11","author":"Simon","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0365","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00431-013-2150-0","article-title":"Pentraxin 3 as a novel early biomarker for the prediction of Henoch-Schonlein purpura nephritis in children","volume":"173","author":"Ge","year":"2014","journal-title":"Eur. J. Pediatr."},{"issue":"10","key":"10.1016\/j.vph.2017.10.003_bb0370","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1111\/ijd.12959","article-title":"Serum levels of alpha-1 acid glycoprotein and pentraxin 3 in patients with Behcet's disease and relationship with disease activity","volume":"54","author":"Yazmalar","year":"2015","journal-title":"Int. J. Dermatol."},{"issue":"4","key":"10.1016\/j.vph.2017.10.003_bb0375","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3109\/08916934.2014.983264","article-title":"Pentraxin 3 as a biomarker of local inflammatory response to vascular injury in systemic lupus erythematosus","volume":"48","author":"Cieslik","year":"2015","journal-title":"Autoimmunity"},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0380","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1253\/circj.CJ-12-0131","article-title":"Diagnosis and assessment of Takayasu arteritis by multiple biomarkers","volume":"77","author":"Ishihara","year":"2013","journal-title":"Circ. J."},{"issue":"3","key":"10.1016\/j.vph.2017.10.003_bb0385","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/art.33411","article-title":"Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia","volume":"64","author":"Baldini","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.vph.2017.10.003_bb0390","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-155-7-201110040-00005","article-title":"Pentraxin-3 as a marker of disease activity in Takayasu arteritis","volume":"155","author":"Dagna","year":"2011","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.vph.2017.10.003_bb0395","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/art.21669","article-title":"Abundance of the long pentraxin PTX3 at sites of leukocytoclastic lesions in patients with small-vessel vasculitis","volume":"54","author":"van Rossum","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.vph.2017.10.003_bb0400","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1002\/1529-0131(200112)44:12<2841::AID-ART472>3.0.CO;2-6","article-title":"PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation","volume":"44","author":"Fazzini","year":"2001","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.vph.2017.10.003_bb0405","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1161\/01.ATV.0000015595.95497.2F","article-title":"Production of the long pentraxin PTX3 in advanced atherosclerotic plaques","volume":"22","author":"Rolph","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.vph.2017.10.003_bb0410","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/path.2314","article-title":"Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions","volume":"215","author":"Savchenko","year":"2008","journal-title":"J. Pathol."},{"issue":"9","key":"10.1016\/j.vph.2017.10.003_bb0415","doi-asserted-by":"crossref","first-page":"837","DOI":"10.5551\/jat.12526","article-title":"Different distribution of pentraxin 3 and C-reactive protein in coronary atherosclerotic plaques","volume":"19","author":"Matsuura","year":"2012","journal-title":"J. Atheroscler. Thromb."},{"issue":"1","key":"10.1016\/j.vph.2017.10.003_bb0420","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2011.06.045","article-title":"Emerging role of high density lipoproteins as a player in the immune system","volume":"220","author":"Norata","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2017.10.003_bb0425","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.vph.2014.11.008","article-title":"Atorvastatin reduces long pentraxin 3 expression in vascular cells by inhibiting protein geranylgeranylation","volume":"67-69","author":"Baetta","year":"2015","journal-title":"Vasc. Pharmacol."},{"issue":"8","key":"10.1016\/j.vph.2017.10.003_bb0430","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1161\/CIRCULATIONAHA.108.806547","article-title":"Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis","volume":"120","author":"Norata","year":"2009","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0435","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s10875-011-9615-6","article-title":"PTX3 is located at the membrane of late apoptotic macrophages and mediates the phagocytosis of macrophages","volume":"32","author":"Guo","year":"2012","journal-title":"J. Clin. Immunol."},{"issue":"4","key":"10.1016\/j.vph.2017.10.003_bb0440","doi-asserted-by":"crossref","first-page":"976","DOI":"10.2215\/CJN.03960907","article-title":"Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease","volume":"3","author":"Suliman","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.vph.2017.10.003_bb0445","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10238-009-0039-z","article-title":"Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile","volume":"9","author":"Zanetti","year":"2009","journal-title":"Clin. Exp. Med."},{"issue":"4","key":"10.1016\/j.vph.2017.10.003_bb0450","doi-asserted-by":"crossref","first-page":"490","DOI":"10.5551\/jat.No613","article-title":"Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia","volume":"16","author":"Ohbayashi","year":"2009","journal-title":"J. Atheroscler. Thromb."},{"issue":"3","key":"10.1016\/j.vph.2017.10.003_bb0455","doi-asserted-by":"crossref","first-page":"278","DOI":"10.5551\/jat.2741","article-title":"Is pentraxin 3 involved in obesity-induced decrease in arterial distensibility?","volume":"17","author":"Miyaki","year":"2010","journal-title":"J. Atheroscler. Thromb."},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0460","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.diabres.2012.11.020","article-title":"Plasma pentraxin 3 levels are associated with carotid IMT in type 1 diabetic patients","volume":"99","author":"Katakami","year":"2013","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"10","key":"10.1016\/j.vph.2017.10.003_bb0465","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/ajh\/hpt103","article-title":"Association of plasma pentraxin 3 with arterial stiffness in overweight and obese individuals","volume":"26","author":"Miyaki","year":"2013","journal-title":"Am. J. Hypertens."},{"issue":"5","key":"10.1016\/j.vph.2017.10.003_bb0470","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.numecd.2013.10.030","article-title":"Pentraxin 3 (PTX3) plasma levels and carotid intima media thickness progression in the general population","volume":"24","author":"Baragetti","year":"2014","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0475","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.3390\/molecules19021651","article-title":"Correlation between inflammatory markers of atherosclerosis and carotid intima-media thickness in Obstructive Sleep Apnea","volume":"19","author":"Ciccone","year":"2014","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.vph.2017.10.003_bb0480","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/jhh.2015.105","article-title":"Elevated pentraxin 3 level at the early stage of exercise training is associated with reduction of arterial stiffness in middle-aged and older adults","volume":"30","author":"Zempo-Miyaki","year":"2016","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.vph.2017.10.003_bb0485","doi-asserted-by":"crossref","first-page":"1417962","DOI":"10.1155\/2016\/1417962","article-title":"Pentraxin 3 is a predictor for fibrosis and arterial stiffness in patients with nonalcoholic fatty liver disease","volume":"2016","author":"Ozturk","year":"2016","journal-title":"Gastroenterol. Res. Pract."},{"key":"10.1016\/j.vph.2017.10.003_bb0490","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ijcard.2016.06.175","article-title":"Serum pentraxin 3 levels are negatively associated with carotid intima media thickness in non-obese rheumatoid arthritis patients","volume":"221","author":"Kahlow","year":"2016","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0495","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.metabol.2014.10.022","article-title":"The impact of obesity on pentraxin 3 and inflammatory milieu to acute aerobic exercise","volume":"64","author":"Slusher","year":"2015","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.vph.2017.10.003_bb0500","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1139\/cjpp-2015-0464","article-title":"Association of pentraxin 3 with insulin resistance and glucose response following maximal aerobic exercise in obese and normal-mass individuals","volume":"94","author":"Slusher","year":"2016","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.vph.2017.10.003_bb0505","doi-asserted-by":"crossref","first-page":"1092738","DOI":"10.1155\/2017\/1092738","article-title":"The potential role of aerobic exercise-induced pentraxin 3 on obesity-related inflammation and metabolic dysregulation","volume":"2017","author":"Slusher","year":"2017","journal-title":"Mediat. Inflamm."},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0510","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jjcc.2011.04.005","article-title":"Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability","volume":"58","author":"Soeki","year":"2011","journal-title":"J. Cardiol."},{"issue":"16","key":"10.1016\/j.vph.2017.10.003_bb0515","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.clinbiochem.2011.08.1141","article-title":"Novel serum biomarkers in carotid artery stenosis: useful to identify the vulnerable plaque?","volume":"44","author":"Hermus","year":"2011","journal-title":"Clin. Biochem."},{"issue":"10","key":"10.1016\/j.vph.2017.10.003_bb0520","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3109\/0886022X.2011.618969","article-title":"Plasma pentraxin 3 is associated with cardiovascular disease in hemodialysis patients","volume":"33","author":"Xu","year":"2011","journal-title":"Ren. Fail."},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0525","doi-asserted-by":"crossref","first-page":"e31474","DOI":"10.1371\/journal.pone.0031474","article-title":"Pentraxin-3 as a marker of advanced atherosclerosis results from the Bruneck, ARMY and ARFY Studies","volume":"7","author":"Knoflach","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0530","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2310\/JIM.0b013e31827c2971","article-title":"Serum pentraxin 3 levels are associated with the complexity and severity of coronary artery disease in patients with stable angina pectoris","volume":"61","author":"Karakas","year":"2013","journal-title":"J. Investig. Med."},{"issue":"9","key":"10.1016\/j.vph.2017.10.003_bb0535","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jcin.2013.04.024","article-title":"Elevated levels of systemic pentraxin 3 are associated with thin-cap fibroatheroma in coronary culprit lesions: assessment by optical coherence tomography and intravascular ultrasound","volume":"6","author":"Koga","year":"2013","journal-title":"JACC Cardiovasc. Interv."},{"issue":"6","key":"10.1016\/j.vph.2017.10.003_bb0540","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/jth.12557","article-title":"Associations of pentraxin 3 with cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis","volume":"12","author":"Jenny","year":"2014","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.vph.2017.10.003_bb0545","doi-asserted-by":"crossref","first-page":"e94073","DOI":"10.1371\/journal.pone.0094073","article-title":"Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial","volume":"9","author":"Miyazaki","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.vph.2017.10.003_bb0550","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s00380-014-0553-0","article-title":"Is pentraxin 3 a biomarker, a player, or both in the context of coronary atherosclerosis and metabolic factors?","volume":"30","author":"Nakamura","year":"2015","journal-title":"Heart Vessel."},{"issue":"4","key":"10.1016\/j.vph.2017.10.003_bb0555","doi-asserted-by":"crossref","first-page":"e007123","DOI":"10.1136\/bmjopen-2014-007123","article-title":"Associations between pentraxin 3 and severity of coronary artery disease","volume":"5","author":"Liu","year":"2015","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.vph.2017.10.003_bb0560","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1159\/000381879","article-title":"Serum pentraxin-3 level in patients who underwent coronary angiography and relationship with coronary atherosclerosis","volume":"24","author":"Nerkiz","year":"2015","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/j.vph.2017.10.003_bb0565","first-page":"6015701","article-title":"Relationship of inflammatory biomarkers with severity of peripheral arterial disease","volume":"2016","author":"Igari","year":"2016","journal-title":"Int. J. Vasc. Med."},{"issue":"1","key":"10.1016\/j.vph.2017.10.003_bb0570","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1536\/ihj.15-248","article-title":"Plasma pentraxin3 level is associated with plaque vulnerability assessed by optical coherence tomography in patients with coronary artery disease","volume":"57","author":"Tazaki","year":"2016","journal-title":"Int. Heart J."},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0575","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.atherosclerosis.2008.05.015","article-title":"Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors","volume":"202","author":"Alberti","year":"2009","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.vph.2017.10.003_bb0580","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1038\/oby.2009.507","article-title":"Reciprocal contribution of pentraxin 3 and C-reactive protein to obesity and metabolic syndrome","volume":"18","author":"Ogawa","year":"2010","journal-title":"Obesity (Silver Spring)"},{"issue":"6","key":"10.1016\/j.vph.2017.10.003_bb0585","doi-asserted-by":"crossref","first-page":"E1254","DOI":"10.1152\/ajpendo.00163.2011","article-title":"Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, whereas visceral adipose tissue PTX3 gene expression is increased in obesity","volume":"301","author":"Osorio-Conles","year":"2011","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.vph.2017.10.003_bb0590","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1475-2840-12-167","article-title":"Obesity and high waist circumference are associated with low circulating pentraxin-3 in acute coronary syndrome","volume":"12","author":"Barazzoni","year":"2013","journal-title":"Cardiovasc. Diabetol."},{"issue":"5","key":"10.1016\/j.vph.2017.10.003_bb0595","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/oby.20695","article-title":"Inflammatory biomarker pentraxin 3 (PTX3) in relation to obesity, body fat depots and weight loss","volume":"22","author":"Witasp","year":"2014","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"10.1016\/j.vph.2017.10.003_bb0600","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.soard.2015.04.013","article-title":"Gastric bypass-induced weight loss alters obesity-associated patterns of plasma pentraxin-3 and systemic inflammatory markers","volume":"12","author":"Barazzoni","year":"2016","journal-title":"Surg. Obes. Relat. Dis."},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0605","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1253\/circj.CJ-15-1303","article-title":"Pentraxin 3 - A link between obesity, inflammation and VASCULAR DISEASE?","volume":"80","author":"Violi","year":"2016","journal-title":"Circ. J."},{"issue":"5","key":"10.1016\/j.vph.2017.10.003_bb0610","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1194\/jlr.M200382-JLR200","article-title":"Characterization of the long pentraxin PTX3 as a TNFalpha-induced secreted protein of adipose cells","volume":"44","author":"Abderrahim-Ferkoune","year":"2003","journal-title":"J. Lipid Res."},{"issue":"8","key":"10.1016\/j.vph.2017.10.003_bb0615","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1210\/jc.2007-1684","article-title":"Calorie restriction modulates inactivity-induced changes in the inflammatory markers C-reactive protein and pentraxin-3","volume":"93","author":"Bosutti","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.vph.2017.10.003_bb0620","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1515\/CCLM.2009.110","article-title":"Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations","volume":"47","author":"Yamasaki","year":"2009","journal-title":"Clin. Chem. Lab. Med."},{"issue":"12","key":"10.1016\/j.vph.2017.10.003_bb0625","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.2215\/CJN.02320311","article-title":"Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease","volume":"6","author":"Miyamoto","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.vph.2017.10.003_bb0630","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1161\/01.CIR.102.6.636","article-title":"PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans","volume":"102","author":"Peri","year":"2000","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.vph.2017.10.003_bb0635","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0008-6363(01)00434-5","article-title":"The inflammatory response in myocardial infarction","volume":"53","author":"Frangogiannis","year":"2002","journal-title":"Cardiovasc. Res."},{"issue":"8","key":"10.1016\/j.vph.2017.10.003_bb0640","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1161\/CIRCULATIONAHA.107.749234","article-title":"Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction","volume":"117","author":"Salio","year":"2008","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.vph.2017.10.003_bb0645","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijcard.2007.07.168","article-title":"Prognostic value of pentraxin 3 in patients with chronic heart failure","volume":"130","author":"Kotooka","year":"2008","journal-title":"Int. J. Cardiol."},{"issue":"12","key":"10.1016\/j.vph.2017.10.003_bb0650","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1084\/jem.190.12.1733","article-title":"C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction","volume":"190","author":"Griselli","year":"1999","journal-title":"J. Exp. Med."},{"issue":"13","key":"10.1016\/j.vph.2017.10.003_bb0655","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1182\/blood.V96.13.4300","article-title":"The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells","volume":"96","author":"Rovere","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.vph.2017.10.003_bb0660","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.2353\/ajpath.2009.080240","article-title":"The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice","volume":"174","author":"Souza","year":"2009","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.vph.2017.10.003_bb0665","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.carpath.2010.02.005","article-title":"PTX3 expression in the heart tissues of patients with myocardial infarction and infectious myocarditis","volume":"20","author":"Nebuloni","year":"2011","journal-title":"Cardiovasc. Pathol."},{"issue":"1","key":"10.1016\/j.vph.2017.10.003_bb0670","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/tri.12197","article-title":"Long pentraxin PTX3 attenuates ischemia reperfusion injury in a cardiac transplantation model","volume":"27","author":"Zhu","year":"2014","journal-title":"Transpl. Int."},{"issue":"10","key":"10.1016\/j.vph.2017.10.003_bb0675","doi-asserted-by":"crossref","first-page":"e13658","DOI":"10.1371\/journal.pone.0013658","article-title":"Whole blood transcriptomics in cardiac surgery identifies a gene regulatory network connecting ischemia reperfusion with systemic inflammation","volume":"5","author":"Liangos","year":"2010","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.vph.2017.10.003_bb0680","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000364996","article-title":"Elevated plasma level of pentraxin-3 predicts in-hospital and 30-day clinical outcomes in patients with non-ST-segment elevation myocardial infarction who have undergone percutaneous coronary intervention","volume":"129","author":"Guo","year":"2014","journal-title":"Cardiology"},{"issue":"1","key":"10.1016\/j.vph.2017.10.003_bb0685","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.atherosclerosis.2009.10.033","article-title":"Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction","volume":"210","author":"Matsui","year":"2010","journal-title":"Atherosclerosis"},{"issue":"16-17","key":"10.1016\/j.vph.2017.10.003_bb0690","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.clinbiochem.2013.08.014","article-title":"Clinical and prognostic implications of circulating pentraxin 3 levels in non ST-elevation acute coronary syndrome","volume":"46","author":"Eggers","year":"2013","journal-title":"Clin. Biochem."},{"issue":"1","key":"10.1016\/j.vph.2017.10.003_bb0695","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1253\/circj.CJ-13-0329","article-title":"Relationships of elevated systemic pentraxin-3 levels with high-risk coronary plaque components and impaired myocardial perfusion after percutaneous coronary intervention in patients with ST-elevation acute myocardial infarction","volume":"78","author":"Kimura","year":"2014","journal-title":"Circ. J."},{"issue":"7","key":"10.1016\/j.vph.2017.10.003_bb0700","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/MCA.0000000000000280","article-title":"Long-term prognostic value of elevated pentraxin 3 in patients undergoing primary angioplasty for ST-elevation myocardial infarction","volume":"26","author":"Akgul","year":"2015","journal-title":"Coron. Artery Dis."},{"issue":"11","key":"10.1016\/j.vph.2017.10.003_bb0705","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1177\/2047487315619733","article-title":"Long-term prognostic utility of pentraxin 3 and D-dimer as compared to high-sensitivity C-reactive protein and B-type natriuretic peptide in suspected acute coronary syndrome","volume":"23","author":"Mjelva","year":"2016","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.vph.2017.10.003_bb0710","doi-asserted-by":"crossref","DOI":"10.14744\/AnatolJCardiol.2016.7307","article-title":"G. Can, M. Eren, Long-term prognostic significance of pentraxin-3 in patients with acute myocardial infarction: 5-year prospective cohort study","author":"Altay","year":"2016","journal-title":"Anatol. J. Cardiol."},{"key":"10.1016\/j.vph.2017.10.003_bb0715","doi-asserted-by":"crossref","first-page":"608414","DOI":"10.1155\/2014\/608414","article-title":"The time profile of Pentraxin 3 in patients with acute ST-elevation myocardial infarction and stable angina pectoris undergoing percutaneous coronary intervention","volume":"2014","author":"Helseth","year":"2014","journal-title":"Mediat. Inflamm."},{"issue":"4","key":"10.1016\/j.vph.2017.10.003_bb0720","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/ATVBAHA.108.178947","article-title":"Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study","volume":"29","author":"Jenny","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.vph.2017.10.003_bb0725","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11883-017-0646-1","article-title":"The role of inflammation in cardiovascular outcome","volume":"19","author":"Montecucco","year":"2017","journal-title":"Curr. Atheroscler. Rep."},{"issue":"3","key":"10.1016\/j.vph.2017.10.003_bb0730","first-page":"187","article-title":"Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype","volume":"38","author":"Horckmans","year":"2017","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.vph.2017.10.003_bb0735","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/JID.2015.346","article-title":"Mesenchymal stromal cell-derived PTX3 promotes wound healing via fibrin remodeling","volume":"136","author":"Cappuzzello","year":"2016","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.vph.2017.10.003_bb0740","doi-asserted-by":"crossref","first-page":"e53133","DOI":"10.1371\/journal.pone.0053133","article-title":"Long pentraxin PTX3 exacerbates pressure overload-induced left ventricular dysfunction","volume":"8","author":"Suzuki","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.vph.2017.10.003_bb0745","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1253\/circj.CJ-08-0157","article-title":"Risk stratification of chronic heart failure patients by multiple biomarkers: implications of BNP, H-FABP, and PTX3","volume":"72","author":"Ishino","year":"2008","journal-title":"Circ. J."},{"issue":"1","key":"10.1016\/j.vph.2017.10.003_bb0750","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ahj.2007.08.013","article-title":"Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure","volume":"155","author":"Suzuki","year":"2008","journal-title":"Am. Heart J."},{"issue":"8","key":"10.1016\/j.vph.2017.10.003_bb0755","doi-asserted-by":"crossref","first-page":"370","DOI":"10.4070\/kcj.2010.40.8.370","article-title":"Pentraxin 3 as a novel marker predicting congestive heart failure in subjects with acute coronary syndrome","volume":"40","author":"Lee","year":"2010","journal-title":"Korean Circ J"},{"issue":"7","key":"10.1016\/j.vph.2017.10.003_bb0760","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacc.2010.10.018","article-title":"Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction","volume":"57","author":"Matsubara","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0765","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ahj.2011.11.007","article-title":"Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study","volume":"163","author":"Dubin","year":"2012","journal-title":"Am. Heart J."},{"issue":"9","key":"10.1016\/j.vph.2017.10.003_bb0770","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/eurjhf\/hfs092","article-title":"of the controlled rosuvastatin multinational trial in heart, G.I.-H.F. trials, pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials","volume":"14","author":"Latini","year":"2012","journal-title":"Eur. J. Heart Fail."},{"issue":"12","key":"10.1016\/j.vph.2017.10.003_bb0775","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.clinbiochem.2013.04.026","article-title":"The role of pentraxin 3 as diagnostic value in classification of patients with heart failure","volume":"46","author":"Duran","year":"2013","journal-title":"Clin. Biochem."},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0780","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1086\/675988","article-title":"Pentraxin-3 and the right ventricle: the Multi-Ethnic Study of Atherosclerosis-Right Ventricle Study","volume":"4","author":"Leary","year":"2014","journal-title":"Pulm. Circ."},{"issue":"4","key":"10.1016\/j.vph.2017.10.003_bb0785","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.000928","article-title":"Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction","volume":"3","author":"Matsubara","year":"2014","journal-title":"J. Am. Heart Assoc."},{"issue":"5","key":"10.1016\/j.vph.2017.10.003_bb0790","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/1753944715578405","article-title":"Value of pentraxin-3 and galectin-3 in acute coronary syndrome: a short-term prospective cohort study","volume":"9","author":"George","year":"2015","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"10.1016\/j.vph.2017.10.003_bb0795","doi-asserted-by":"crossref","first-page":"159051","DOI":"10.1155\/2015\/159051","article-title":"Prognostic value of pentraxin-3 level in patients with STEMI and its relationship with heart failure and markers of oxidative stress","volume":"2015","author":"Tomandlova","year":"2015","journal-title":"Dis. Markers"},{"key":"10.1016\/j.vph.2017.10.003_bb0800","doi-asserted-by":"crossref","first-page":"817615","DOI":"10.1155\/2015\/817615","article-title":"Pentraxin-3 predicts long-term cardiac events in patients with chronic heart failure","volume":"2015","author":"Liu","year":"2015","journal-title":"Biomed. Res. Int."},{"issue":"1-2","key":"10.1016\/j.vph.2017.10.003_bb0805","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0165-5728(00)00214-9","article-title":"Inducible expression of the long pentraxin PTX3 in the central nervous system","volume":"106","author":"Polentarutti","year":"2000","journal-title":"J. Neuroimmunol."},{"issue":"13","key":"10.1016\/j.vph.2017.10.003_bb0810","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1002\/mds.23871","article-title":"Increases of pentraxin 3 plasma levels in patients with Parkinson's disease","volume":"26","author":"Lee","year":"2011","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.vph.2017.10.003_bb0815","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/1352458512457845","article-title":"Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica","volume":"19","author":"Wang","year":"2013","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.vph.2017.10.003_bb0820","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/jcbfm.2013.224","article-title":"The acute-phase protein PTX3 is an essential mediator of glial scar formation and resolution of brain edema after ischemic injury","volume":"34","author":"Rodriguez-Grande","year":"2014","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"4","key":"10.1016\/j.vph.2017.10.003_bb0825","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/STROKEAHA.115.012133","article-title":"Astrocyte-derived pentraxin 3 supports blood-brain barrier integrity under acute phase of stroke","volume":"47","author":"Shindo","year":"2016","journal-title":"Stroke"},{"issue":"1-2","key":"10.1016\/j.vph.2017.10.003_bb0830","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2010.07.001","article-title":"Analysis of glial secretome: the long pentraxin PTX3 modulates phagocytic activity of microglia","volume":"229","author":"Jeon","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.vph.2017.10.003_bb0835","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12974-014-0227-y","article-title":"Pentraxin 3 mediates neurogenesis and angiogenesis after cerebral ischaemia","volume":"12","author":"Rodriguez-Grande","year":"2015","journal-title":"J. Neuroinflammation"},{"issue":"2","key":"10.1016\/j.vph.2017.10.003_bb0840","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.atherosclerosis.2011.11.036","article-title":"Pentraxin 3: a novel and independent prognostic marker in ischemic stroke","volume":"220","author":"Ryu","year":"2012","journal-title":"Atherosclerosis"},{"issue":"19","key":"10.1016\/j.vph.2017.10.003_bb0845","first-page":"4112","article-title":"PTX3 expression in the plasma of elderly ACI patients and its relationship with severity and prognosis of the disease","volume":"20","author":"Qin","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189117301817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189117301817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:17:25Z","timestamp":1761527845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189117301817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":169,"alternative-id":["S1537189117301817"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2017.10.003","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on the role of Pentraxin 3 in atherosclerosis and cardiovascular diseases","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2017.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}